ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2329

Increase of CD4+CD25+FoxP3+ T Cell in Patients with Systemic Sclerosis Could Secret IL-17 with Dysfunction of Immunosuppression

Xinjuan Liu1, Na Gao1, Mengtao Li1, Dong Xu1, Yong Hou1, Qian Wang1, Guohua Zhang1, Qiuning Sun2, Henghui Zhang3 and Xiaofeng Zeng4, 1Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, 2Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, 3Hepatology Institute, Peking University, People's Hospital, Beijing, China, 4Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: interleukins (IL), regulatory cells and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: T-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

 Immune unbalance between Th17 and regulatory T cells (Treg) is a characteristic of systemic sclerosis (SSc). The functional heterogeneity and differentiation dynamics can be clearly shown by separating Treg cells into three subsets based on the expression of FoxP3and CD45RA. The aim of this study was to investigate subsets levels of Treg from the patients with naive SSc and assess their roles in the immune balance between Treg and Th17.

Methods:

Peripheral blood from 31 patients with SSc and 33 health controls were collected. Peripheral blood mononuclear cells (PBMCs) were prepared and analyzed for the expression of CD4, CD25, CD45RA, CTLA-4, CD69, CD279, GITR, FoxP3 and IL-17 with flow cytometry. Measuring Treg suppressive capacity against proliferation of CD4+CD25– T cells in coculture experiments by a CFSE based. The expression of FoxP3, CTLA-4, IL-17A and RORC mRNA were studied with real-time PCR.

Results:

(1)The frequency of CD4+CD25+FoxP3+Treg cells were significantly elevated in patients with SSc (3.62±1.14) compared with controls (1.97±0.75, P<0.001), but the expression of CTLA-4 and its mRNA were lower in Treg cells of SSc patients compared with control with diminished immunosuppression capacity.

 (2) In the patients with SSc, the frequency of CD45RA–FoxP3high activated Treg cells (aTreg,FrII) were lower than control (0.25±0.16 vs 0.66±0.41 among CD4+, P<0.001; 12.42±5.23 vs 30.01±1.74 among Treg, P<0.001),CD45RA–FoxP3lo T cell (FrIII) were higher than control(6.23±2.29 vs 2.90±0.91 among CD4+, P<0.001; 73.71±9.62 vs 57.96±9.90 among Treg, P<0.001),There were no significant difference in two groups with CD45RA+FoxP3loTreg cells (rTreg,FrI),which were relatively lower in Treg cells (1.87±0.94 vs 1.63±0.97 among CD4+, P=0.320; 23.19±10.60 vs 29.63±11.77 among Treg, P=0.025).

(3)In the patients with SSc, immunosuppressive capacity of aTreg and rTreg cells were diminished,FrIII cells had no immunosuppressive capacity neither in the patients with SSc nor with control; in the patients with SSc, the expression of CTLA-4 in the surface of FrII and FrIII cells were decreased significantly (P<0.001,respectively), and CTLA-4 mRNA expression in FrII were decreased.

(4) The expression of IL-17 were higher in FrIII cells than FrI and FrII cells in both groups (P<0.001,respectively),but there were no difference of FrIII between these two groups; Th17 cells were increased in the patients with SSc (P<0.001); in the patients with SSc, CD25+FoxP3+IL17+cells among CD4+cells were increased(0.075±0.032 vs 0.049±0.027, P=0.029),but no difference of  CD25+FoxP3+IL17–with control; the expression of IL-17A and RORC mRNA were increased in the FrIII cells of SSc patients(P<0.001,respectively).

Conclusion:

Decreased aTreg with functional deficiency and increased CD45RA–FoxP3lo T cells could explain increased Treg with dysfunction in the patients with SSc, which were the reasons of unbalance of Treg and Th17 cells in the patients with SSc too. Increased Treg cells were not the real regulatory T cells, but non-suppressive CD45RA–FoxP3lo cells, which is the main provider for FoxP3+IL-17+ cells without immunosuppressive capacity.


Disclosure:

X. Liu,
None;

N. Gao,
None;

M. Li,
None;

D. Xu,
None;

Y. Hou,
None;

Q. Wang,
None;

G. Zhang,
None;

Q. Sun,
None;

H. Zhang,
None;

X. Zeng,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increase-of-cd4cd25foxp3-t-cell-in-patients-with-systemic-sclerosis-could-secret-il-17-with-dysfunction-of-immunosuppression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology